Anticancer titanium agents

Bibliography

• ROSENBERG B, VAN CAMP L: Platinum compounds a new class of potent antitumour agents. Nature(1969) 222:385–386.
   PubMed Web of Science ®Google Scholar
• PIL E LIPPARD S: Cisplatin and related drugs. In: Encyclopedia of Cancer.Bertino JR (Ed.), Academic Press, San Dieg,o CA, USA (1997):392–410.
   Google Scholar
• CHU G: Cellular responses to cisplatin. Biol. Chem.(1994) 269:787–790.
   Google Scholar
• TAKAHARA PM, FREDERICK CA, LIPPARD, SJ: Crystal structure of the anticancer drug cisplatin bound to duplex DNA. J. Am. Chem. Soc.(1996) 118:12309–12321.
   Web of Science ®Google Scholar
• KOPF-MAIER P: Complexes other than platinum as antitumour agents. Eur. I Clin. Pharmacol.(1994) 47:1–16.
   PubMed Web of Science ®Google Scholar
• •A concise description of metal (non-platinum) antitumour agents.
   Google Scholar
• PIEPER T, BORSKY K, KEPPLER BK: Non-platinum antitumour compounds. In: Topics in biological inorganic chemistry Clarke MJ, Sadler PJ (Eds.), Springer, Berlin, Germany (1999):172–199.
   Google Scholar
• KRATZ E SCHÜTTE MT: Anticancer metal complexes and tumour targeting strategies. Cancer J.(1998) 11:176–182.
   Google Scholar
• KEPPLER BK, FRIESEN C, VONGERICHTEN H, VOGEL E: Budotitane, a new tumor-inhibiting titanium compound in preclinical and clinical development. In: Metal complexes in cancer chemotherapyKeppler BK (Ed.), VCH Weinheim, Germany (1993):297–323.
   Google Scholar
• •A comprehensive report on the promising properties of the first Ti compounds to reach clinical trials.
   Google Scholar
• MERHOTRA RC, BOHRA R, GAUR DP:Meta113-Diketonates and Allied Derivatives. Academic Press, London UK (1978).
   Google Scholar
• KEPPLER BK, BERGER MR, HEIM ME: New tumor-inhibiting metal complexes. Cancer Treat. Rev(1990) 17:261–277.
   PubMed Web of Science ®Google Scholar
• KEPPLER BK, DIEZ A, SEIFRIED V: Antitumor activity of phenyl substituted dihalogenobis (1-phenyl- 1, 3-butanedionato)titanium(IV) compounds. Armeim-Forsch. Drug Res.(1985) 35:1832–1836.
   PubMedGoogle Scholar
• KEPPLER BK, FRIESEN C, MORITZ HG, VONGERICHTEN H, VOGEL E: Tumor-inhibiting bis(I3-diketonato)metal complexes. Budotitane, the first transition metal complex after platinum to qualify for clinical trials. Struct. Bond.(1991) 78:97–127.
   Google Scholar
• BERGER MR, SEELIG MH, GALEANO A: Metal complexes with specific activity against colorectal tumors evaluation of a tumor model close to the clinical situation. In: Metal complexes in cancer chemotherapyKeppler BK (Ed.), VCH Weinheim, Germany (1993):327–349.
   Google Scholar
• KEPPLER BK, SCHMAHL D: Preclinical evaluation of dichlorobis(1-phenyl-1,3-butanedionato)titanium(IV) and budotitane. Armeim-Forsch. Drug Res.(1986) 36:1822–1828.
   PubMedGoogle Scholar
• SCHILLING T, KEPPLER BK, HEIM ME et al:Clinical Phase land pharmacokinetic trial of the new titanium complex budotitane. Invest. New Drugs(1996) 13:327–332.
   PubMed Web of Science ®Google Scholar
• KOPF-MAIER P, KOPF H: Transition and main-group metal cyclo-pentadienyl complexes preclinical studies on a series of antitumour agents of different structural type. Struct. Bond.(1988) 70:103–185.
   Google Scholar
• •Excellent review of early studies on metal-Cp antitumour agents.
   Google Scholar
• KOPF-MAIER P, KOPF H: Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma. Arzneim-Forsch. Drug Res.(1987) 37:532–534.
   Google Scholar
• KOPF-MAIER E GERLACH S: Pattern of toxicity by titanocene dichloride in mice. Blood and urine chemical parameters. 1. Cancer Res. Clin. °Ilea(1986) 111:243–247.
   Google Scholar
• SCHMOLL HJ: Titansalze in der Tumortherapie. Internist. Prax.(1996) 36:577–579.
   Google Scholar
• BERDELL WE, SCHMOLL HJ, SCHEULEN ME et al:Phase I evaluation of the new antineoplastic compound titanocene dichloride in adults with solid tumors. Onkologie(1993) 16\(Suppl. 3):R172.
   Google Scholar
• KORFEL A, SCHEULEN ME, SCHMOLL HJ et al.:Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clin Cancer Res.(1998) 4:2701–2708.
   PubMed Web of Science ®Google Scholar
• CHRISTODOULOU CV, FERRY DR, FYFE DW et al.:Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. 1. Clin. Oncol(1998) 16:2761–2769.
   Google Scholar
• KOPF-MAIER P, KOPF H.: Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes - early transition metal antitumour drugs. In: Metal Compounds in Cancer TherapyFricker SP (Ed.), Chapman and Hall, London, UK (1994):109–146.
   Google Scholar
• SCHROEDER HA, BALASSA JJ, TRIPTON IH: Abnormal trace metals in man titanium. 1. Chron. Dis.(1963) 16:55–69.
   PubMedGoogle Scholar
• SUN H, HONGZHE L, WEIR R, SADLER PJ: The fist specific Ti(IV)-protein complex potential relevance to anticancer activity of titanocenes. Angew. Chem. Int. Ed.(1998) 37:1577–1579.
   PubMedGoogle Scholar
• GUO M, SUN H, MCARDLE HJ, GAMBLING L, SADLER PJ: TiIV uptake and release of human serum transferrin and recognition of Ti1V-transferrin by cancer cells understanding the mechanism of action of the anticancer drug titanocene dichloride. Biochemistry(2000) 39:10023–10033.
   PubMed Web of Science ®Google Scholar
• •Highly recommended for anyone interested in bioinorganic chemistry. A key paper for understanding metal transport in cells.
   Google Scholar
• MESSORI L, ORIOLI P, BANHOLZER V, PAIS I, ZATTA P: Formation of titanium(IV) transferrin by reaction of human serum apotransferrin with titanium complexes. FEBS Lett.(1999) 443:157–161.
   Google Scholar
• KOPF-MAIER P: Intracellular localizationof titanium with xenografted sensitive human tumors after treatment with the antitumour agent titanocene dichloride. I Struct. Biol.(1990) 105:35–45.
   Google Scholar
• FRUEHAUF S, ZELLER WJ: New platinum, titanium and ruthenium complexes with patterns of DNA damage in rat ovarian tumor cells. Cancer Res.(1991) 51:2943–2948.
   PubMedGoogle Scholar
• HARDING MM, MOKDSI G: Antitumour metallocenes structure-activity studies and interactions with biomolecules. Cun: Med. Chem.(2000) 7:1289–1303.
   PubMed Web of Science ®Google Scholar
• •Extensive coverage of metallocene antitumour compounds that complements an early overview [16].
   Google Scholar
• CHRISTODOULOU CV, ELIOPOULOS AG, YOUNG LS, HODGKINS L, FERRY DR, KERR DJ: Anti-proliferative activity and mechanism of action of titanocene dichloride. Br. J. Cancer(1998) 77:2088–2097.
   PubMed Web of Science ®Google Scholar
• COZAK D, MARDHY A, OLIVIER MJ, BEAUCHAMP AL: N7/06 chelation in a complex with an analogue of guanine. Preparation, spectroscopic study and crystal structure of bisfi15-cyclopentadienyfi (theophyllinato)titanium(III). Inorg. Chem.(1986) 25:2600–2606.
   Google Scholar
• BEAUCHAMP AL, COZAK D, MARDHY A: Synthesis and crystal structure of chloro-bis(115-cyclopentadienyfi purinato titanium(IV), a model for the interaction of the antitumor titanocene dichloride molecule with DNA bases. 'twig. Chim. Acta.(1984) 92:191–197.
   Google Scholar
• MCLAUGHLIN ML, CROMAN JM, SCHALLER TR, SNELLING RD: DNA-metal binding in antitumor-active metallocene dichlorides from inductively coupled plasma spectroscopy analysis titanocene dichloride forms DNA-Cp2Ti or DNA- CpTiadducts depending on pH. 1 Am. Chem. Soc.(1990) 112:8949–8952.
   Google Scholar
• KEPPLER BK, HEIM ME: Antitumour- active bis-I3-diketonato metal complexes budotitane - a new anticancer agent. Drugs Fut.(1988) 13:637–652.
   Google Scholar
• KOPF-MAIER P, TORNIEPORT-OETTING IC: Antitumor activity of titanocene amino acid complexes. BioMetals(1996) 9:267–271.
   PubMed Web of Science ®Google Scholar
• CARUSO F, ROSSI M, TANSKI J et al:Synthesis, structure and antitumor activity of a novel tetranuclear titanium complex. 1. Med. Chem.(2000) 43:3665–3670.
   Google Scholar
• PATEL HM: Liposomes as a controlled-release system. Biochem. Soc. Trans.(1985) 2:513–516.
   Google Scholar
• TROYANOV SI, GORBENKO OY: Crystal and molecular structure of cyclo- tetrakis(bis(2 2, 6, 6-tetramethyl-heptane-3,5-dionato)titanium Mill, pentane adduct. Polyhedron(1997) 16:777–780.
   Google Scholar
• CARROL KG, TULLIS JL: Presence of titanium and zinc in human leukocytes. Nature(1968) 217:1172–1173.
   PubMedGoogle Scholar
• SCHWIETERT CH, MCCUE JP: Coordination compounds in medicinal chemistry. Coord. Chem. Rev(1999) 184:67–89.
   Web of Science ®Google Scholar
• KOHLSTAEDT LA, WANG J, FRIEDMAN JM, RICE PA, STEITZ TA: Crystal structure at 3.5A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science(1992) 256:1783–1790.
   Google Scholar
• KAWASAKI C: Photokilling of T-24 human bladder cancer cells with titanium dioxide molecules. Yokohama Igaku(1995) 46:103–110.
   Google Scholar
• FUJISHIMA A, CAI RX, OTSUKI J et al:Biochemical application of photoelectrochemistry killing of malignant cells with titanium dioxide powder. Electrochim. Acta(1993) 38:153–157.
   Google Scholar
• XU M, MA J, GU J, LU Z: Photocatalytic TiO2 nanoparticles damage to cellular membranes and genetic supramolecules. Supramol Sci.(1998) 5:511–513.
   Google Scholar
• HUANG N, XU M, YUAN C et al:The study of photokilling effect and mechanism of ultrafine TiO2 particles on U937 cells. 1. Photochem. Photobiol.(1997) 108:229–233.
   Web of Science ®Google Scholar
• GONZALES JB, PURDON MA, HOROWITZ SM: In vitrostudies on the role of titanium in aseptic loosening. Clin. Orthop.(1996) 330:244–250.
   Google Scholar
• ROGERS SD, HOWIE DW, HAYNES DR, PEARCY MJ: The in vitroresponse to particulate titanium alloy. ASTM Spec. Tech. Publ.(1996) STP1272:297-305. 978Expert Op/n. Ther. Patents (2001)11(6)
   Google Scholar
• TONEY JH, MARKS J: Hydrolysis chemistry of the metallocene dichlorides M(5-05H5)2C15, M Ti, V, Zr. Aqueous kinetics, equilibria and mechanistic implications for a new class of antitumor agents. J. Am. Chem. Soc.(1985) 107:947–953.
   Google Scholar